Weekly Deal Watch: Cannabis Brands And Hemp Firms Become Takeover Targets

This weekly series from Marijuana Business Daily and Viridian Capital Advisors provides the latest data on cannabis investment activity and M&A, along with key takeaways, analysis and trends based on recent market moves.

The data below, provided by Viridian Capital Advisors, is through the week ended Feb. 22.

Capital raise highlights:

Innovative Industrial Properties (NYSE: IIPR), a cannabis industry-focused real estate investment trust, closed a $144 million raise – capital it plans to use to purchase properties to lease back to marijuana operators. “As more investors come in that don’t want to touch the plant, they could be more open to this type of real estate investment opportunity,” said Harrison Phillips, vice president with Viridian Capital Advisors.
Boston-based Ascend Wellness Holdings, a multistate vertically integrated marijuana operator, closed a $55 million funding round – capital the firm will use to expand in its home state of Massachusetts and other markets, including Ohio. “Massachusetts’ adult-use market operators continue attracting capital due to more near-term growth prospects,” Phillips noted.

M&A highlights:

Green Thumb Industries (CSE: GTII) of Chicago closed its acquisition of Los Angeles-based For Success Holding Co., owners of the Beboe product line of premium cannabis and CBD-infused products. The all-stock deal, the value of which was not disclosed, underscores growing demand among branded product companies by larger operators looking to boost their product portfolios, Phillips said. “Local and regional brands that are differentiating themselves are generating a lot of interest and remain attractive for acquisition,” he said.
After the passage of the U.S. Farm Bill, hemp and CBD companies continue to be top acquisition targets as underscored by two recent deals:
- GNCC Capital’s $120 million acquisition of BioCann Pharma, a CBD oil producer and distributor with offices in Colombia and Burlington, Ontario, Canada.
- Youngevity International’s $16 million acquisition of Florida-based Khrysos, a manufacturer of hemp-based CBD extraction equipment.

Viridian Capital Advisors is a financial and strategic advisory firm that provides investment banking, M&A, corporate development and investor relations services to emerging growth companies and qualified investors in the cannabis sector.

Original Article Source: https://mjbizdaily.com/brands-hemp-firms-takeover-targets/

Comments

Could CBD Lead To The Development Of Safer Antipsychotic Medications?

Antipsychotic medications are important for managing a number of different psychiatric ailments, including bipolar disorders, schizophrenia, and even dementia. These drugs can greatly improve the manageability of symptoms that often distort one’s experience of reality. They can also create major mood disruptions and lead to a number of behavioral and emotional difficulties. Antipsychotic and anti-psychosis medications can be life-changing for people with such disorders, enabling them to live more normal and manageable lives without their symptoms taking over. These drugs work by regulating neurotransmitters in the brain so that naturally occurring imbalances and dysfunctions no longer disrupt mental and emotional processes. Often, reaching this outcome is much easier said than done; it can take a lot of time to find courses and combinations of treatments that work. It’s sometimes necessary to make adjustments to find the right balance for the individual and it’s not unusual for outc...

Cannabis Watch: Canopy Growth To Book Charge Of Up To $568 Million As Marijuana Restructuring Continues

Canopy Growth Corp. said early Thursday it was halting a range of operations across three continents and expects its restructuring plans to result in a charge of up to C$800 million (567.9 million) in the fiscal fourth quarter. U.S.-traded shares US:CGC CA:WEED of the cannabis company fell 1.9% in afternoon trading. Canopy said it was selling operations in Africa, curtailing cultivation of hemp in the U.S. and Columbia, and shutting down an indoor production facility in Canada. The announcement will result in 85 job cuts, the company said. “When I arrived at Canopy Growth in January, I committed to conducting a strategic review in order to lower our cost structure and reduce our cash burn,” Canopy Chief Executive David Klein said in a statement. Read: As cannabis industry stays largely quiet on coronavirus, this CEO has been sounding the alarm Canopy’s restructuring announcement was expected by investors, Cowen analyst Vivien Azer wrote in a note to clients Thursday. Azer rate...

Can Medical Marijuana Help Aging Parents With Dementia?

For decades, marijuana, even for medical uses, was demonized or questioned. When states like Colorado legalized it for recreational use, more studies began to determine provable efficacy for its use as a medicine. The Federal government still classifies marijuana the same way it classifies heroin: harmful and with no medical benefits. Now we can see that this is wrong. When states legalized marijuana, referred to as cannabis here, they had an interest in getting data to see what good it could do. Proving efficacy could increase medical marijuana sales, benefit people who might at least find some medical use, and overall would bring tax dollars into the state coffers. Without funding studies, the Federal government has done very little to demonstrate what good cannabis can do. After all, if the presumption is that it helps nothing, there would be no motivation to determine with scientific data that it does anyone any good. But we have convincing data now about its beneficial use ...

Norma Pence

Search This Blog